ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio6.49
Quick Ratio5.76
Price-To-Earnings
Trailing P/E Ratio150.18
Forward P/E Ratio103.12
P/E Growth4.06
Sales & Book Value
Annual Sales$593.75 million
Price / Sales26.89
Cash Flow$2.6193 per share
Price / Cash135.82
Book Value$15.57 per share
Price / Book22.85
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins25.71%
Return on Equity18.91%
Return on Assets16.64%
Miscellaneous
Employees1,143
Outstanding Shares44,880,000
Market Cap$16.96 billion
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, July, 26th. The medical equipment provider reported $1.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $1.15. The medical equipment provider had revenue of $180.01 million for the quarter, compared to the consensus estimate of $173.87 million. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The business's revenue was up 35.9% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
What price target have analysts set for ABMD?
8 analysts have issued 12-month price objectives for ABIOMED's stock. Their forecasts range from $280.00 to $480.00. On average, they expect ABIOMED's stock price to reach $363.1429 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for ABIOMED.
What is the consensus analysts' recommendation for ABIOMED?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD) and Penumbra (PEN).
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)
- Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
- Mr. Ian McLeod, VP & Corp. Controller
Has ABIOMED been receiving favorable news coverage?
Media coverage about ABMD stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ABIOMED earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 46.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for ABIOMED.
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.30%), Baillie Gifford & Co. (4.72%), Renaissance Technologies LLC (3.46%), FMR LLC (1.54%), Bank of New York Mellon Corp (1.43%) and Waddell & Reed Financial Inc. (1.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which major investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Winslow Capital Management LLC, Winslow Capital Management LLC, American Century Companies Inc., Bank of New York Mellon Corp, Janus Henderson Group PLC, OppenheimerFunds Inc. and Castleark Management LLC. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.
Which major investors are buying ABIOMED stock?
ABMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Carillon Tower Advisers Inc., Sumitomo Mitsui Trust Holdings Inc., Massachusetts Financial Services Co. MA, Advisors Asset Management Inc., Schwab Charles Investment Management Inc. and Putnam Investments LLC. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $358.08.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $16.96 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
